Article
Combined treatment with Epimedium koreanum Nakai extract and gefitinib overcomes drug resistance caused by T790M mutation in non-small cell lung cancer cells.
Nutrition and cancer - 1 Jan 2014
Song Jie, Zhong Rongling, Huang Houcai, Zhang Zhenhai, Ding Dongmei, Yan Hongmei, Sun E, Jia Xiaobin
Abstract excerpt
Although the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors, such as gefitinib, have shown promising therapeutic efficacy in nonsmall cell lung cancer (NSCLC) patients harboring EGFR activating mutation, development of acquired resistance is almost inevitable. We investigated whether the addition of Epimedium koreanum Nakai extract (EEF) to gefitinib could overcome the resistance of NSCLC...
Topics
- Animals
- Antineoplastic Agents
- Carcinoma, Non-Small-Cell Lung
- Cell Cycle
- Cell Line, Tumor
- Cell Proliferation
- Cell Survival
- Combined Modality Therapy
- Drug Resistance, Neoplasm
- Drug Synergism